Xaira Therapeutics, a San Francisco, CA-based built-in AI biotechnology firm, launched with greater than $1 Billion of dedicated capital.
Backers included ARCH Enterprise Companions and Foresite Capital, F-Prime, NEA, Sequoia Capital, Lux Capital, Lightspeed Enterprise Companions, Menlo Ventures, Two Sigma Ventures, the Parker Institute for Most cancers Immunotherapy (PICI), Byers Capital, Rsquared, and SV Angel, amongst others.
Led by CEO, Dr. Marc Tessier-Lavigne, former Chief Scientific Officer of Genentech and former President of Rockefeller and Stanford Universities, Xaira Therapeutics is an built-in biotechnology firm making use of product growth, organic and medical knowledge technology, and AI strategies analysis, each translational and elementary, to all steps of the drug discovery and growth course of.
The manager group additionally consists of co-founder Dr. Hetu Kamisetty, previously of Meta and the Institute for Protein Design; Dr. Arvind Rajpal, previously of Genentech; and Dr. Don Kirkpatrick, previously of Interline and Genentech
Xaira was additionally co-founded by Dr. David Baker, Professor of Biochemistry and Director of the Institute for Protein Design on the College of Washington College of Medication.
The board of administrators at the moment consists of:
- Vikram Bajaj, Ph.D, Co-Founder and CEO, Foresite Labs; Managing Director, Foresite Capital
- Carolyn Bertozzi, Ph.D., Baker Household Director of Sarafan ChEM-H; Anne T. and Robert M. Bass Professor; Professor (by courtesy) of Chemical and Programs Biology and of Radiology, Stanford College; Investigator, Howard Hughes Medical Institute; Nobel Prize (2022)
- Kaye Foster, M.B.A., Senior Advisor, The Boston Consulting Group, and former SVP, International Human Assets, Onyx Prescribed drugs, former CHRO, Johnson & Johnson
- Alex Gorsky, M.B.A., Former Chairman and CEO, Johnson & Johnson
- Scott Gottlieb, M.D., Former FDA Commissioner, Companion, NEA
- Stephen Knight, M.D., President & Managing Companion, F-Prime
- Mathai Mammen, M.D., Ph.D., Chairman and CEO of FogPharma and Former EVP, Prescribed drugs R&D, Johnson & Johnson
- Robert Nelsen, M.B.A., Co-Founder and Managing Director, ARCH Enterprise Companions
- Richard Scheller, Ph.D., Chairman of R&D, BridgeBio; former Chief Scientific Officer and Head of Therapeutics at 23andMe, and the previous Government Vice President of Analysis and Early Growth at Genentech; Lasker Award (2013)
- Marc Tessier-Lavigne, Ph.D., CEO Xaira; former President, Stanford College & Rockefeller College; former Chief Scientific Officer, Genentech
- Bryan White, M.B.A. Chair, Advisory Board, the Institute for Protein Design; Co-Founder and Chief Funding Officer, Sahsen Ventures; former CIO Quadra/Quellos and Blackrock Different Advisors
Commenting on the information Marc Tessier-Lavigne stated: “Now, witnessing how AI is impacting different industries and the appreciable progress in functions of AI in biology, I consider we’re poised for a revolution. Xaira is in a powerful place to each advance elementary AI analysis and translate these advances into transformative new medicines, and I’m excited to have the chance to guide the group.”
FinSMEs
24/04/2024
